Skip to main content
. Author manuscript; available in PMC: 2015 Sep 28.
Published in final edited form as: Cancer Lett. 2013 Aug 21;352(1):28–35. doi: 10.1016/j.canlet.2013.08.026

Figure 2.

Figure 2

Breast and prostate cancer cell lines are sensitive to docetaxel, doxorubicin, and mitoxantrone in vitro. Results are presented as the ratio of viable cells following 24 h of drug administration to the number of viable cells in the control sample. (A) BT20 cells treated with docetaxel. (B) BT20 cells treated with doxorubicin. (C) PC3 cells treated with docetaxel. (D) PC3 cells treated with mitoxantrone. Figures are representative of two independent experiments.